In summary, this proof-of-principle study shows that in vivo molecular imaging of the PD-1/PD-L1 axis in NSCLC using 18F-BMS-986192, and 89Zr-nivolumab is feasible and safe in humans. The gene discussed is CD274; the disease is non-small cell lung carcinoma.